The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy

Background: The programmed death 1 (PD1)/programmed death ligand 1 (PDL1) targeted therapies have gained positive outcomes in several tumors, but the evidence of the expression and prognosis value of PD1/PDL1 in high risk prostate cancer was rare. Methods: Immunohistochemical analysis of PDL1/PD1 ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Heng, Wang, Zhize, Zhang, Yucong, Sun, Guoliang, Ding, Beichen, Yan, Libin, Liu, Haoran, Guan, Wei, Hu, Zhiquan, Wang, Shaogang, Cheng, Fei, Xu, Hua, Zhang, Xu, Ye, Zhangqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603373/
https://www.ncbi.nlm.nih.gov/pubmed/31289580
http://dx.doi.org/10.7150/jca.30384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603373/
https://www.ncbi.nlm.nih.gov/pubmed/31289580
http://dx.doi.org/10.7150/jca.30384

Ejemplares similares